Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Hemophilia A Clinical Trial

Official title:

A Multicenter, Open, Single Arm Evaluation of the Efficacy, Safety and Pharmacokinetics of Recombinant Human Coagulation FVIII (SCT800) in Prophylaxis Therapy on Patients With Severe Hemophilia A Who Had Previously Treated With FVIII.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03815318
• Other study ID #: SCT800-A 302
• Status: Completed
• Phase: Phase 3
• Start date: January 21, 2019
• Est. completion date: January 16, 2020

Study information

• Verified date: February 2020
• Source: Sinocelltech Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multi-center, open-label, single-arm trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (≥12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII:C) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from V1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.

Description:

After subjects pass screening, prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week for 6 months. Subjects shall receive FVIII intravenous injection treatment at the study site or at home. During the study prophylaxis treatment period, subjects should return for visit every four weeks, namely for Visit (V) 2 (4 weeks ± 4 days), Visit 3 (8 weeks ± 4 days), Visit 4 (12 weeks ± 4 days), Visit 5 (16 weeks ± 7 days), Visit 6 (20 weeks ± 7 days), Visit 7 (24 weeks ± 7 days) and end-of-treatment (EOT) visit (+ 14 days). Of which, blood collection shall be carried out during the screening period and in V1, V2, V4, V7 and the EOT visit for FVIII inhibitor assay; blood collection shall be carried out before and after the completion of SCT800 infusion in V1, V4 and V7 for incremental in-vivo recovery (IVR) assay.

FVIII:C activity shall be monitored before injection and 15minutes(min), 30min, 1h, 3h, 6h, 9h, 12h, 24hours(h), 28h, 32h and 48h after injection at V1 and V7. Then pharmacokinetics parameters (incremental in-vivo recovery, t1/2 etc.) of SCT800 shall be calculated and evaluated.

5 subjects may receive elective surgical treatment within the prophylaxis treatment period (after the first drug administration in day 0).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: January 16, 2020
• Est. primary completion date: January 16, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 12 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged =12 years old and =65 years old;

• Male patients who are clinically diagnosed with severe (laboratory tested FVIII:C <1%) hemophilia A, including historical FVIII:C <1%;

• Previously received FVIII treatment (prophylactic or bleeding treatment), have the relevant records and are verified to have accumulated exposures days( EDs) =150 days;

• The bleeding treatment records of at least 3 months before screening can be obtained;

• Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result <0.6 BU(Bethesda unit)/mL);

• The prothrombin time is normal or international normalized ratio (INR) =1.5; 7. Platelet count =100 × 109/L;

Exclusion Criteria:

• Known allergy to recombinant coagulation factor VIII concentrate or any excipient; known allergy to bovine, rodent or hamster bovine;

• Has a history or family history of blood coagulation factor VIII inhibitor;

• Clinical liver function test (glutamic-pyruvic transaminase, glutamic-pyruvic transaminase) = three times the upper limit of normal (ULN) or clinical kidney function test (blood urea nitrogen, creatinine) = three times the ULN;

• Patients clinically diagnosed with active Hepatitis B or Hepatitis C;

• Patients with other coagulation dysfunction diseases in addition to hemophilia A;

• Patients with severe heart disease, including myocardial infarction and cardiac dysfunction of class III or above;

• Patients who previously experienced intracranial bleeding;

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Drug:
• Recombinant Human Coagulation FVIII
Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.

Locations

Country	Name	City	State
China	Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Tianjin

Sponsors (4)

Lead Sponsor	Collaborator
Sinocelltech Ltd.	Chinese Academy of Medical Sciences, Parexel, Q2 Solutions

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of FVIII inhibitors	The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial.	up tp 24 weeks
Primary	Annualized Bleeding Rate	Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)	up to 24 weeks
Secondary	Annualized joint bleeding rate	Annualized joint bleeding rate(AJBR) can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25).	up to 24 weeks
Secondary	FVIII incremental in-vivo recovery	Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as [IU/ml]/[IU/kg]	Predose within 30 min,15 min±2 min?1 hour±5 min.
Secondary	Bleeding event treatment efficacy	The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).	up to 24 weeks
Secondary	Elimination Half Life	t1/2; One-stage aPTT Clotting Assay and Chromogenic Assay	Predose within 30 min,15 min±2 min?30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.
Secondary	Clearance	CL; One-stage aPTT Clotting Assay and Chromogenic Assay	Predose within 30 min,15 min±2 min?30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.
Secondary	Area Under the Curve to the Last Measurable Timepoint	AUClast;One-stage aPTT Clotting Assay and Chromogenic Assay	Predose within 30 min,15 min±2 min?30 min±2 min,1 hour±5 min,3 hours±5 min,6 hours±5 min,9 hours±10 min,12hours h±10 min,24 hours±10 min,28 hours±10 min,32 hours±10 min and 48 hours±10 min post-dose.